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Type 2 inflammatory responses (T helper type 2 
[TH2] cells, IL-4, 5,13, IgE, eosinophils, ba-
sophils, mast cells, alternatively activated macro-
phages, and goblet cell metaplasia) are generated 
in over 3 billion people worldwide that suffer 
from allergic disease or harbor parasitic hel-
minth infections (Baena-Cagnani, 2001; Braman, 
2006; Nair et al., 2006; Brooker, 2010; Brooker 
et al., 2010). Although there has been much 
progress in the understanding of mechanisms 
responsible for allergen-driven airway hyperre-
activity (AHR) and the expulsion of gastroin-
testinal (GI) nematodes, the initiation of these 
responses remains poorly understood (Paul and 
Zhu, 2010). Current hypotheses have focused 
on mucosal epithelia as an important source of 
cytokines that drive type 2 responses (Fallon 
et al., 2006; Neill et al., 2010; Paul and Zhu, 
2010). However, few, if any, studies have 
uncovered the molecular mechanisms that link 
mucosal injury with the preferential induction 
of TH2 responses.
IL-33 (IL-1-F11) is a unique IL-1 family 
cytokine produced from damaged epithelia 
that utilizes NF-B and MAPK activation to 
promote type 2 inflammation through the IL-1 
receptor–related protein ST2 (Ali et al., 2007; 
Humphreys et al., 2008; Kurowska-Stolarska 
et al., 2008, 2009; Rankin et al., 2010). Epi-
thelia and myeloid lineage cells at the mucosal 
interface may release IL-33 as an alarmin for 
the rapid induction of IL-13–driven immunity 
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The molecular mechanisms that drive mucosal T helper type 2 (TH2) responses against 
parasitic helminths and allergens remain unclear. In this study, we demonstrate in mice 
that TFF2 (trefoil factor 2), an epithelial cell–derived repair molecule, is needed for the 
control of lung injury caused by the hookworm parasite Nippostrongylus brasiliensis and for 
type 2 immunity after infection. TFF2 is also necessary for the rapid production of IL-33,  
a TH2-promoting cytokine, by lung epithelia, alveolar macrophages, and inflammatory 
dendritic cells in infected mice. TFF2 also increases the severity of allergic lung disease 
caused by house dust mite antigens or IL-13. Moreover, TFF2 messenger RNA expression is 
significantly increased in nasal mucosal brushings during asthma exacerbations in children. 
These experiments extend the biological functions of TFF2 from tissue repair to the initia-
tion and maintenance of mucosal TH2 responses.
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with the hookworm Nippostrongylus brasiliensis. Our results 
indicate that TFF2 (a) promotes type 2 lung immunopathol-
ogy induced by allergen or IL-13, (b) controls the extent of 
lung injury caused by migratory infectious stage larvae (L3), 
and (c) modulates early TH2 development. This mechanism 
involves rapid, coordinated IL-33 production from lung epi-
thelia, alveolar macrophages, and inflammatory DCs. IL-33 
induction requires the putative TFF2 receptor, CXCR4, 
but occurs independently of the TLR adaptor molecule 
MyD88. Collectively, these experiments demonstrate an 
important role for TFF2 in the regulation of IL-33 release 
at mucosal surfaces and the development of type 2 im-
mune responses.
RESULTS
TFF2 expression is a central feature  
of asthma in humans and mice
TFF2 expression is induced within airway epithelial cells of 
mice challenged with allergen or type 2 cytokines (Nikolaidis 
et al., 2003; Follettie et al., 2006). To determine whether in-
creased TFF2 expression was a feature of human asthma, we 
obtained nasal mucosa biopsies from pediatric patients ex-
periencing asthma exacerbations and compared their TFF2 
messenger RNA (mRNA) levels to nonasthmatic control 
subjects. TFF2 was significantly elevated in asthma patients 
over controls (Fig. 1 A), which prompted us to evaluate the 
biological role of TFF2 in the pathogenesis of murine 
asthma driven by house dust mite (HDM) antigens or IL-13 
administration. Exposure of TFF2/ mice to HDM antigens 
caused significantly less AHR (Fig. 1 B) and reduced the 
numbers of eosinophils and neutrophils recruited into the 
bronchoalveolar lavage (BAL), as compared with HDM-
sensitized WT mice (Fig. 1 C). There were no differences 
between naive WT and TFF2/ mice in the numbers of 
eosinophil or neutrophil precursors within the BM (not 
depicted). This may suggest that TFF2/ mice have the 
(Préfontaine et al., 2010). However, the mechanisms that 
regulate IL-33 release and whether IL-33 functions as a cyto-
kine or nuclear factor remain unclear (Carriere et al., 2007; 
Ohno et al., 2009). Although epithelial cell death by necrosis 
may serve as one mechanism for IL-33 release, recent evi-
dence shows that viral infection can result in IL-33 produc-
tion from alveolar macrophages (Chang et al., 2011). 
Furthermore, IL-33 administration to mice infected with the 
GI nematode Trichuris muris promotes worm expulsion 
(Humphreys et al., 2008), but the endogenous mechanisms 
that regulate IL-33 production during worm infection are 
currently unknown.
Trefoil factor family peptides (TFF1–3) are protease- 
resistant mediators that serve critical roles in mucosal barrier 
function and repair (Podolsky, 1997; Paulsen et al., 2008). 
These proteins are constitutively released within the mucus 
gel layer that covers ocular, urinary, respiratory, and GI sur-
faces (Taupin and Podolsky, 2003). Furthermore, the trefoil 
motif, which resembles a three-leaf clover, is highly con-
served among TFF proteins from frogs to humans (Taupin 
and Podolsky, 2003). TFFs are produced from epithelia, 
fibroblasts, and tissue macrophages within hours of injury 
to promote epithelial cell restitution through mechanisms 
that may require CXCR4, the putative TFF2 receptor 
(Dubeykovskaya et al., 2009). As such, TFF2 promotes organ 
regeneration and healing in several injury models (Farrell 
et al., 2002; Poulsen et al., 2005; Fox et al., 2007; Kurt-Jones 
et al., 2007). TFF2 expression is up-regulated during tissue 
injury associated with allergic lung inflammation in mice 
through STAT-6–dependent and –independent mechanisms 
(Nikolaidis et al., 2003, 2006) However, its absence did not 
affect lung inflammation or mucus metaplasia (Nikolaidis 
et al., 2006). Thus, its biological importance in the context of 
type 2 immunopathologies is not well understood.
This study investigated whether TFF2 served any role in 
the development of allergic lung disease or after infection 
Figure 1. Clinical asthma is marked by  
increased TFF2 expression, and TFF2/ mice 
are resistant to HDM-induced murine asthma. 
(A) Quantification of TFF2 mRNA transcripts from 
nasal mucosal brushings of normal subjects  
(n = 9) or patients experiencing acute asthma exacer-
bation (n = 23). Each dot represents an individual 
patient. Vertical bars indicate the mean. (B) Airway 
pressure time index (APTI) of WT and TFF2/ 
mice after immunization with 1× PBS or HDM 
antigen extract. Means ± SE of eight mice/group 
are shown. (C) Quantification of inflammatory 
cells recovered from the BAL fluid of WT and 
TFF2/ mice after intratracheal administration of 
HDMs or saline. Means ± SE of four mice/group 
are shown. Data are representative of two to 
three independent experiments (*, P < 0.05;  
**, P < 0.01). n.d., not detected.
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pattern for TFF2 was consistent with the kinetics of parasite 
migration through the host and suggested a potential role for 
this molecule in each mucosal compartment.
To investigate whether TFF2 served a critical function 
within hookworm-infected lungs, we compared lung histology 
between infected WT and TFF2/ strains. Although naive 
TFF2/ lung tissue showed moderately enlarged alveolar 
space at baseline, infected TFF2/ animals developed excessive 
lung hemorrhage at day 1 and enlarged distal airspaces from al-
veolar wall destruction at days 3 and 7 after infection (Fig. 3 B). 
In contrast, WT mice developed focal hemorrhagic lesions 
around migrating parasites at day 1 after inoculation, followed 
by a progressive closure of the damaged areas of lung tissue at 
days 3 and 7 after inoculation (Fig. 3 B). To quantitatively mea-
sure lung injury, the numbers of erythrocytes within the BAL 
fluid were counted from cohorts of WT and TFF2/ mice 
between days 0 and 7 after infection (Meyer et al., 1998). Fig. 3 
C shows that from as early as day 1 after infection, TFF2/ 
lung tissues had significantly greater numbers of erythrocytes 
than the WT strain and remained elevated over the course of 
observation. This was consistent with the histological evidence 
of excessive lung hemorrhage in the absence of TFF2.
TFF2 was also necessary for chronic lung repair after 
N. brasiliensis infection–induced injury. At day 28 after infection, 
when parasites were no longer present (not depicted), TFF2/ 
mice had much less collagen deposition within their lungs, as 
determined by histological staining (Fig. 3 D) and measurement 
of hydroxyproline (essential component of collagen; Fig. 3 E). 
TFF2/ mice did show less destruction of alveolar walls dur-
ing the chronic repair phase (day 28), as compared with the 
acute injury phase (day 3), which implies redundancy between 
TFF2 and many other wound-healing mechanisms (Barron 
and Wynn, 2011; Brancato and Albina, 2011). Thus, N. brasiliensis 
infection–induced TFF2 production 
within the lung promotes both tissue 
repair and fibrosis.
normal potential to produce granulocytes but show impaired 
allergic airway inflammation in response to HDM antigens.
We also investigated whether the TFF2 deficiency mod-
ulated the development of type 2 allergic lung disease in an 
IL-13–driven model of murine asthma (Wills-Karp et al., 
1998). rIL-13–treated WT C57BL/6 mice developed robust 
AHR, goblet cell metaplasia, and eosinophilic airway inflam-
mation; however, these responses were significantly attenu-
ated in TFF2/ mice (Fig. 2, A–C). Moreover, IL-13–treated 
TFF2/ mice showed impaired induction of lung mRNA 
transcripts for the goblet cell–specific genes MUC5AC, 
CLCA3, and RETNLB (Fig. 2 D), as well as the alternatively 
activated macrophage marker RETNLA (Fig. 2 D). Collec-
tively, these findings suggest that TFF2 deficiency protects 
mice against experimental asthma induced by allergen or IL-13 
and that increased TFF2 expression in asthma patients is asso-
ciated with disease exacerbation.
TFF2 regulates hookworm-mediated lung injury
TFF2 production can be rapidly induced, within minutes of 
mucosal injury (Taupin et al., 1999), as well as during allergen-
induced inflammation (Taupin et al., 1999; Nikolaidis 
et al., 2003). We investigated whether TFF2 regulated tissue 
repair and/or TH2-dependent host immunity against the para-
sitic helminth N. brasiliensis. In this model, migratory L3 enter 
the lung tissues between 0 and 2 d after infection and cause 
hemorrhagic tissue injury that resolves over several weeks 
after infection (Marsland et al., 2008). Subsequently, by day 3 
after infection, >90% of worms have exited the lung and enter 
the small intestine (Herbert et al., 2009). As shown in Fig. 3 A, 
TFF2 mRNA levels increased over threefold within the lung 
at day 1 and within the jejunum at day 3 after infection of WT 
C57BL/6 mice with 500 N. brasiliensis L3. This expression 
Figure 2. TFF2 is required for IL-13–
driven allergic airway inflammation and 
airway hyperresponsiveness. (A) Airway 
pressure time index (APTI) of WT and TFF2/ 
mice was measured 8 d after administration 
of rIL-13 (5 µg/mouse) or vehicle (1× PBS). 
Data represent mean ± SE of eight mice/
group. (B) Quantification of PAS-positive cells 
within airway epithelium at day 8 after injec-
tion of rIL-13 or PBS. Data represent mean ± 
SE of eight mice/group. (C) Numbers of epi-
thelia, macrophages, eosinophils, and lym-
phocytes in BAL fluid at day 8 after injection 
of rIL-13 or PBS. Data represent mean ± SE of 
eight mice/group. (D) Quantification of mRNA 
transcripts encoding RETNLB, MUC5AC, 
CLCA3, and RETNLA in the lung at day 8 after 
injection of rIL-13 or PBS. Data represent 
mean ± SE of four to six mice/group. Data are 
representative of four independent experi-
ments (***, P < 0.001).
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Thus, immunity against N. brasiliensis 
adult worms in the intestine is accom-
panied by increased TFF2 production. 
In the absence of TFF2, more worm 
eggs are passed into the environment 
and parasites reside within their hosts 
for longer periods of time.
TFF2 promotes an early TH2 response  
during N. brasiliensis infection
IL-4 and IL-13 are both necessary and sufficient for host pro-
tection against most GI nematodes (Finkelman et al., 2004) 
and most allergic lung immunopathologies (Wills-Karp et al., 
1998). Given that TFF2/ mice had significant defects in 
both worm clearance and allergic lung pathology, we postu-
lated that TFF2 might promote type 2 cytokine production. 
Consistent with this hypothesis, TFF2/ mice displayed de-
fects in both the early (lung) and late (intestinal) stages of 
N. brasiliensis infection. In the early phase, TFF2/ mice ex-
pressed fewer IL-4 and IL-13 lung mRNA transcripts than 
WT mice at day 3 after inoculation (Fig. 5 A). Intracellular 
IL-13 staining of TCR-+CD4+ cells within the lung drain-
ing LNs (Fig. 5 B and Fig. S1) revealed that at day 3 after in-
fection, TFF2/ mice produced three- to fourfold less IL-13 
than infected WT animals (Fig. 5, B and C), yet there were no 
obvious differences in T cell recruitment to the LN between 
these strains.
TFF2 promotes worm expulsion from the GI tract
TFF2 was also rapidly induced within the GI tract after the 
entry of worms into the intestinal lumen. We did not find any 
gross histological evidence of gut injury caused by N. brasiliensis 
in either WT or TFF2/ mice (not depicted). Therefore, 
we investigated whether TFF2 promoted the clearance of 
lumen-dwelling worms from infected mice. As shown in 
Fig. 4 A, the numbers of parasites that initially migrated from 
the lung to the intestine on day 3 were not different between 
WT and TFF2/ strains. However, worm expulsion, which 
is an IL-4– and IL-13–dependent process (Finkelman et al., 
2004), was significantly impaired in TFF2/ mice at days 7 
and 12, in comparison with the WT strain (Fig. 4 A). Similarly, 
TFF2/ mice harbored significantly more worm eggs in their 
stool, as compared with WT controls between days 7 and 10 
after infection (Fig. 4 B). TFF2 was secreted into the gut lumen 
of infected WT mice at day 7 after infection, which correlated 
with the onset of worm expulsion, whereas the lack of 
TFF2 was associated with increased worm burden (Fig. 4 C). 
Figure 3. Hookworm infection induces 
the expression of TFF2, which limits 
hemorrhagic lung injury but promotes 
fibrosis and airway hyperresponsiveness. 
(A) Time course evaluation of TFF2 mRNA 
transcript levels in lung and jejunum of  
N. brasiliensis–infected WT C57BL/6 mice. 
Means ± SE of five to six mice/group are shown. 
(B) Masson’s Trichrome staining for collagen 
(green) on paraffin-embedded lung tissues  
of naive mice or after infection with 500  
N. brasiliensis larvae at the indicated time points. 
Erythrocytes stain crimson red. Representative 
images are shown. (C) Numbers of erythro-
cytes in the BAL fluid of WT versus TFF2/ 
mice infected with 500 N. brasiliensis larvae 
at the indicated time points. Means ± SE of 
five to six mice/group are shown. Data are 
representative of two to three independent 
experiments (*, P < 0.05; **, P < 0.01).  
(D) Masson’s Trichrome staining for collagen 
(green) on paraffin-embedded lung tissues of 
WT and TFF2/ mice on day 28 after infection 
with 500 N. brasiliensis larvae. Representative 
images are shown. (E) Hydroxyproline content of 
lung tissue at day 28 after infection. Each point 
represents an individual lobe of lung. The dotted 
line indicates the level of hydroxyproline in naive 
WT mouse lung (*, P < 0.05). Horizontal bars 
indicate the mean. Data are representative of 
two independent experiments. Bars, 100 µm.
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mechanisms were further investigated. Although 
there are multiple epithelial cell–derived cytokines 
that can promote type 2 immunity (Ito et al., 2005; 
Schmitz et al., 2005; Saenz et al., 2010), we focused 
on IL-33 (IL-1-F11), an IL-1 family cytokine which 
has been reported to elicit TH2-associated inflam-
mation after its release from damaged epithelial cells 
(Schmitz et al., 2005; Carriere et al., 2007; Kurowska-
Stolarska et al., 2009). Strikingly, N. brasiliensis– 
infected WT mice produced highly elevated IL-33 
levels within the BAL fluid at both days 1 and 3 after 
infection (Fig. 6 A). In contrast, TFF2/ mice produced 
very low amounts of IL-33 at these time points (Fig. 6 A).
To identify the potential cellular sources of IL-33, our 
initial experiments focused on lung epithelia and macro-
phage/DC lineage cells within whole lung digests. We used 
mAb specific for either epithelial cell adhesion molecule 
(EpCAM), which is expressed broadly on epithelial cells, or 
CD11c, which is highly expressed on alveolar macrophages/
DCs (van Rijt et al., 2005; Trzpis et al., 2007). Once isolated 
by magnetic bead sorting, IL-33 mRNA transcript levels 
were determined from 106 cells of each population. Surpris-
ingly, IL-33 expression was induced in both lung epithelia 
(Fig. 6 B) and macrophages/DCs (Fig. 6 C) from N. brasiliensis–
infected WT mice at days 1 and 3 after infection. However, 
parasitized TFF2/ mice only slightly increased their IL-33 
mRNA levels in these cell populations (Fig. 6, B and C). 
Similar differences in IL-33 levels between strains were 
detected by immunofluorescence staining (not depicted).
To specifically determine whether lung epithelia or al-
veolar macrophages produced IL-33 at the protein level, 
we evaluated these populations by flow cytometry. Our 
gating strategy defined lung epithelia as EpCAM+, CD45, 
and MHC class II, to exclude the large population of 
EpCAM+ cells that coexpressed CD45+ (common leukocyte 
antigen; Fig. 6 D). In WT mice, N. brasiliensis infection 
caused a 10-fold increase of IL-33+ lung epithelia at day 1 
after infection but only a fourfold increase by day 3 (Fig. 6 E). 
In contrast, TFF2/ lung epithelia showed moderate dif-
ferences after infection that were not significant (Fig. 6, 
F and G). This demonstrates that TFF2 is necessary for the 
rapid, but transient induction of IL-33 within lung epithe-
lia after N. brasiliensis infection.
During the later stages of N. brasiliensis infection, TFF2/ 
mice secreted less IL-4 than WT animals at day 7 after infec-
tion (Fig. 5 D). Also, compared with WT controls, TFF2/ 
mice had significantly fewer intestinal mRNA transcripts 
for RELM- (Resistin-like molecule ), an IL-4/IL-13– 
dependent goblet cell–derived cytokine which is both neces-
sary and sufficient for the normal expulsion of N. brasiliensis 
adult worms from the GI tract (Fig. 5 E; Herbert et al., 2009). 
However, these defects were transient, as TFF2/ mice pro-
duced IL-4 and expressed RELM- transcripts at levels equiv-
alent to infected WT mice by day 12 after infection (Fig. 5 E), 
which was closely associated with the ability of TFF2/ mice 
to eventually clear worm infection by day 14 after infection.
Based on these observations, we hypothesized that the 
delay in IL-4 secretion, RELM- production, and worm clear-
ance in TFF2/ mice resulted from a proximal defect in type 2 
cytokine production. To directly test this possibility, we admin-
istered rIL-4 to mice in the form of IL-4/anti–IL-4 mAb 
complexes (IL-4C; Finkelman et al., 1993) to infected WT or 
TFF2/ mice on days 0 and 4 followed by quantitation of 
adult worm numbers at day 8 after infection. As predicted, 
IL-4C administration to TFF2/ mice dramatically increased 
RELM- production (Fig. 5 F) and successfully cleared intes-
tinal worms (Fig. 5 G). Collectively, these data indicate that the 
delayed immunity against N. brasiliensis in TFF2/ animals 
results from an early defect in type 2 cytokine production.
TFF2 is required for hookworm-induced  
IL-33 production within lung epithelia  
and alveolar macrophages
Given that early IL-4 and IL-13 production was significantly 
impaired in worm-infected TFF2/ mice, the underlying 
Figure 4. TFF2 promotes spontaneous expulsion and ter-
mination of egg production during N. brasiliensis infection. 
(A) N. brasiliensis intestinal worm numbers recovered from WT 
versus TFF2/ mice at the indicated time points after a primary 
infection. Means ± SE of 8–10 mice/group are shown. n.d., not 
detected. (B) N. brasiliensis fecal egg numbers in WT versus 
TFF2/ mice after a primary infection. Means ± SE of 8–10 
mice/group are shown. (C) Immunostaining for Tff2 protein 
(magenta precipitate indicated by arrows) in paraffin-embedded 
sections of jejunum from N. brasiliensis–infected WT (top) or 
TFF2/ (bottom) mice at day 7 after infection. Bars, 70 µm. Data 
are representative of four independent experiments (*, P < 0.05; 
**, P < 0.01).
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Figure 5. Early defect TH2 expansion and RELM- expression in TFF2/ mice is responsible for delayed immunity against N. brasiliensis 
infection. (A) IL4 and IL13 mRNA transcripts in naive WT and TFF2/ mice or 3 d after N. brasiliensis infection. Means ± SE of five to six mice/group are 
shown. (B) Representative dot plot showing IL-13–positive CD4+ lymphocytes within the LN of naive WT and TFF2/ mice or 3 d after N. brasiliensis  
infection. Four individual mice/group were analyzed for infected samples, whereas naive LNs were pooled from two to three mice. (C) Mean percentage 
(±SE) of IL-13–positive CD4+ lymphocytes from the experiment described in B. (D) Serum IL-4 abundance, as determined by in vivo cytokine capture assay 
at 0, 7, and 12 d after infection. Means ± SE of five to six mice/group are shown. (E) Intestinal RELM- mRNA transcript levels at 0, 7, and 12 d after  
infection. Means ± SE of five to six mice/group are shown. (F) N. brasiliensis intestinal worms recovered from intestinal lumen on day 8 from WT versus 
TFF2/ mice that were injected with vehicle or rIL-4/anti–IL-4 complexes (IL-4C) at days 0 and 4. Means ± SE of five to six mice/group are shown. 
n.d., not detected. (G) Immunofluorescence staining for RELM- within the jejunum of mice from the experiment described in F. Cell nuclei stained with DAPI. 
Bars, 50 µm. Data are representative of three to four independent experiments (*, P < 0.05; **, P < 0.01).
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macrophages also up-regulated IL-33 
production at both days 1 and 3 after 
infection. In contrast, these IL-33+ al-
veolar macrophages were significantly 
less abundant within TFF2/ lung 
tissues at both time points (Fig. 6, 
J and K). Overall, this indicates that 
TFF2 promotes IL-33 mRNA and 
protein expression in lung epithelia 
and alveolar macrophages within the 
first 3 d after hookworm infection.
TFF2 deficiency impairs IL-33 production  
from inflammatory DCs, and IL-33 is necessary  
for host immunity against N. brasiliensis
Inflammatory DCs have been shown as critical drivers for the 
in vivo differentiation of TH2 cells (Hammad et al., 2010; 
Phythian-Adams et al., 2010). Therefore, it was important to 
Given that TFF2 regulated IL-33 from lung epithelia, we 
investigated whether it was also important for IL-33 produc-
tion from alveolar macrophages. Our gating strategy defined 
alveolar macrophages as CD11b, CD11c+, CD317+/, 
Ly6G/C, and CD103 (Fig. 6 H; Lambrecht and Hammad, 
2009). Results shown in Fig. 6 I demonstrate that WT 
Figure 6. TFF2 is necessary for N. brasiliensis– 
induced IL-33 production from lung  
epithelial cells and alveolar macrophages. 
(A) Levels of IL-33 within the BAL fluid of  
WT and TFF2/ mice after N. brasiliensis 
infection. Means ± SE of four to five mice/
group are shown. (B and C) IL33 mRNA  
levels within EpCAM+ (B) or CD11c+ cells  
(C; 106 total cells) sorted from the lungs of 
naive or N. brasiliensis–infected WT and 
TFF2/ mice with magnetic beads. Means ± 
SE of four individual mice/group are shown.  
(D) Gating strategy for the identification of 
lung epithelia from whole lung tissue as 
FSCHiSSCMed, EpCAM+, CD45, and MHC class 
II cells. Representative data from a WT 
mouse at day 3 after infection stained intra-
cellularly with a PE-labeled isotype control 
IgG. (E and F) Representative dot plots show-
ing intracellular IL-33 staining within WT or 
TFF2/ lung epithelia at the indicated times 
after N. brasiliensis infection. Numbers indi-
cate the percentage of positive cells.  
(G) Quantification of the experiment de-
scribed in E and F that shows the mean ± SE 
of four individual mice/group. (H) Gating 
strategy for the identification of alveolar 
macrophages from whole lung tissue as 
CD11b, CD11c+, LyCG/C, CD317+/, and 
CD103. (I and J) Representative dot plots 
showing intracellular IL-33 staining within 
WT or TFF2/ alveolar macrophages at the 
indicated times after N. brasiliensis infection. 
Numbers indicate the percentage of positive 
cells. (K) Quantification of the experiment 
described in I and J that shows the mean ± SE 
of four individual mice/group. Data are repre-
sentative of two to four independent experi-
ments for each genotype analyzed per time 
point (*, P < 0.05; **, P < 0.01).
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differences in naive mice (Fig. 7 B) or at day 1 after infection 
(not depicted).
Although ST2+IL-33+ inflammatory DCs were a rela-
tively small population within the MLNs of N. brasiliensis– 
infected WT mice, intact ST2 signaling in the host served a 
critical role for the development of host immunity. Data 
shown in Fig. 8 indicate that treatment of WT C57BL/6 
mice with two 750-µg doses of neutralizing anti-ST2 mAb 
significantly increased both parasite egg production (Fig. 8 A) 
and the numbers of adult hookworms recovered from the 
intestine at day 9 after infection (Fig. 8 B). Thus, TFF2 pro-
motes IL-33 production from inflammatory DCs during the 
early stages of hookworm infection, and neutralization of 
ST2 (IL-33 receptor) impairs the normal expulsion of N. brasil-
iensis adult worms from infected hosts.
Given this novel role for TFF2 in the rapid production of 
IL-33 from a variety of cellular sources, we sought to deter-
mine whether the administration of rTFF2 was alone suffi-
cient to induce a type 2 response. As eosinophils are a hallmark 
of type 2 inflammation and are constitutively fluorescent 
within IL-4 reporter mice (4Get; Voehringer et al., 2006), 
we inoculated naive 4Get animals i.p. with 4 µg rTFF2 over 
4 d and evaluated whether these cells were recruited to the 
peritoneal cavity on day 5. rTFF2 administration selectively 
increased the percentage of eosinophils as compared with 
PBS treatment but did not increase the percentage of macro-
phages, PMNs, or lymphocytes (Fig. 9 A). rTFF2 administra-
tion did not increase the percentage of mast cells or basophils 
(not depicted). Importantly, ST2 was required for this effect 
because the increase of peritoneal eosinophils (FSCMed 
SScHiSiglec-F+, GFP+) was abrogated by the treatment of mice 
with anti-ST2 mAb during rTFF2 administration (Fig. 9 B). 
This is consistent with evidence that rIL-33 administration to 
determine whether TFF2 also regulated IL-33 production in 
this important cell population. Inflammatory DCs within medi-
astinal LNs (MLNs) were defined as CD11b+CD11c+MHC 
class II+ and FcRI+ (Fig. 7 A; Hammad et al., 2010). Inflam-
matory DCs that coexpressed ST2 and IL-33 increased five-
fold in percentage by day 3 after infection within WT 
mice, but this population was distinctly IL-33neg within 
TFF2/ MLNs (Fig. 7, B and C). We did not detect these 
Figure 7. TFF2 is required for inflammatory DCs to express IL-33 
within the lung draining LNs after N. brasiliensis infection.  
(A) Gating strategy for the identification of inflammatory DCs as 
CD11b+, CD11c+, FcR1+, and MHC class II+ within the MLNs. (B) Plots 
are gated on inflammatory DCs in MLNs of naive WT and TFF2/ mice 
or day 3 after infection with N. brasiliensis. Numbers indicate the per-
centage in each quadrant. (C) Percentage of IL-33+, TI/ST2+ inflamma-
tory DCs from the experiment described in B. TI/ST2 (also known as 
IL-1RL1) is a critical subunit of the murine IL-33 receptor. Means ± SE 
of four mice/group are shown. Data are representative of three inde-
pendent experiments (** P < 0.01).
Figure 8. ST2 is necessary for host immunity against N. brasilien-
sis. (A) N. brasiliensis fecal egg numbers in WT C57BL/6 mice after treat-
ment with anti-T1/ST2 mAb or isotype control on days 0 and 4. Means ± 
SE of six mice/group are shown. (B) N. brasiliensis intestinal worm num-
bers at day 9 after infection from the experiment described in A. Means ± 
SE of six mice/group are shown. Data are representative of two indepen-
dent experiments (*, P < 0.05; **, P < 0.01; and ***, P < 0.001).
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mechanism regarding the production of this type 2–promoting 
cytokine (Fig. 10 A).
To directly test whether TFF2-induced IL-33 production 
alone was sufficient to drive TH2 cell differentiation from 
naive T cell precursors, rTFF2-exposed BMDMs were used to 
stimulate naive OVA-specific CD4+ T cells (OTII). T cell lin-
eage commitment was determined by mRNA quantification 
for levels of the following transcription factors: TBET/TBX21 
(TH1), GATA3 (TH2), RORC (TH17), and FOXP3 (Treg). 
Within 96 h of co-culture, rTFF2-treated, OVA-pulsed 
BMDMs increased GATA3 expression nearly 10-fold, whereas 
co-cultures containing naive OTII cells with mock-treated, 
OVA-pulsed BMDMs did not up-regulate GATA3 (Fig. 10 B). 
Interestingly, rTFF2 treatment moderately suppressed TBET, 
RORC, and FOXP3 expression compared with mock-treated, 
OVA-pulsed BMDMs (Fig. 10 B). Targeted knockdown of 
IL-33 in BMDMs blocked TFF2-driven GATA3 expression and 
IL-13 production but increased TBET expression and IFN- 
production (Fig. 10, C and D). Moreover, rTFF2-treatment 
of OVA-pulsed BM-derived DCs (BMDCs) also caused a 
significant up-regulation of GATA3 expression within the 
OVA-specific OTII cells (Fig. 10 E). Overall, these findings 
demonstrated that TFF2 functioned as a specific stimulus for 
IL-33 production, which, at least in this in vitro co-culture 
system, functioned to selectively drive 
antigen-specific TH2 differentiation 
from naive T cell precursors.
TFF2-induced IL-33 production 
requires CXCR4 but not  
ST2 or MyD88
To investigate the mechanisms required 
for TFF2-mediated IL-33 production, 
naive mice results in the rapid and selective recruitment of 
eosinophils (Schmitz et al., 2005). Collectively, these data 
show that increased levels of TFF2 are sufficient to rapidly 
induce eosinophil recruitment through a mechanism that is 
dependent on the IL-33 receptor ST2.
TFF2 drives antigen-specific TH2 differentiation  
through IL-33
Although our data indicated that TFF2 was required for IL-33 
production, it remained unclear whether TFF2 could di-
rectly stimulate IL-33 release. As macrophages are known 
to produce more IL-33 than DCs (Ohno et al., 2009), we 
generated WT BM-derived macrophages (BMDMs) and 
treated these cells with rTFF2 and/or bacterial LPS fol-
lowed by quantitation of mRNA transcripts for the canoni-
cal TH2-promoting cytokines, IL-33, IL-25, and thymic 
stromal lymphopoietin (TSLP). Surprisingly, TFF2 itself was 
a selective stimulus for IL-33, whereas TFF2 alone did not 
induce expression of IL-25 or TSLP (Fig. 10 A). As ex-
pected, LPS alone induced a moderate increase of IL-33, 
but co-administration of TFF2 and LPS actually reduced 
IL-33 levels compared with TFF2 alone (Fig. 10 A). In con-
trast, co-administration of TFF2 and LPS stimulated a signifi-
cant increase of IL-25, which suggested a possible synergistic 
Figure 9. Administration of rTFF2 to 
naive mice induces eosinophilia through 
an IL-33–dependent mechanism. (A) Naive 
IL-4 fluorescent reporter mice (4Get) were 
administered four daily i.p. injections of 1 µg 
rTFF2 or PBS and analyzed on day 5, and the 
percentage of inflammatory leukocytes from 
cytospin preparations of peritoneal lavage 
fluid were determined by Giemsa staining. 
Means ± SE of four mice per group are 
shown (**, P < 0.01). (B) Flow cytometry dot 
plots showing the gating strategy used to 
identify GFP+Siglec-F+ cells within the  
peritoneal cavity after the same treatments 
as described in A, but combined with the 
administration of anti-ST2 mAb or isotype-
matched control Ig on days 0, 2, and 4. The 
percentage of total cells within the gated 
population is shown in the top right corner 
of each plot. The bottom plots are gated on 
cells shown within the corresponding top 
plot gates. Data represent mean ± SE of four 
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with the CXCR4 antagonist AMD3100 
completely blocked TFF2-mediated IL-33 
mRNA expression and protein release 
(Fig. 10 G). Collectively, these data indicate 
that TFF2 functions through CXCR4, not 
MyD88, for the induction of IL-33 produc-
tion by BMDMs.
Lastly, to determine whether BMDMs required autocrine 
IL-33 signaling to promote TH2 differentiation, we generated 
BMDMs from ST2/ mice. Data show that TFF2-treated, 
OVA-pulsed BMDMs from ST2/ mice induced signifi-
cantly more GATA3 expression within OVA-specific OTII 
cells as compared with nontreated ST2/ BMDMs (Fig. 10 H). 
Thus, TFF2-mediated effects on macrophages did not re-
quire MyD88 or autocrine IL-33 signaling but were depen-
dent on CXCR4, the putative TFF2 receptor.
we initially focused on MyD88, the critical adaptor molecule 
for most Toll-like receptor and IL-1 cytokine signaling pathways 
(Takeuchi and Akira, 2002). Contrary to expectation, TFF2-treated 
BMDMs from MyD88/ mice resulted in slightly greater 
levels of GATA3 than induced by WT BMDMs; however, 
this was not significant (Fig. 10 F). Next, we asked whether 
TFF2 induced IL-33 release from macrophages through 
mechanisms that required the putative TFF2 receptor CXCR4 
(Dubeykovskaya et al., 2009). Treatment of WT BMDMs 
Figure 10. TFF2-treated antigen-presenting 
cells selectively drive TH2 differentiation through 
an IL-33–dependent mechanism. (A) BMDMs from 
WT mice were evaluated for mRNA expression levels 
of IL33, IL25, and TSLP after exposure to media (MED), 
100 ng/ml LPS, 40 ng/ml rhTFF2 (TFF2), or LPS and 
TFF2 for 48 h. Mean ± SE of quadruplicate wells is 
shown. (B) Quantification of mRNA transcripts for 
GATA3, TBX21, RORC, and FOXP3 in co-cultures of 
OTII CD4+ T cells and BMDMs that were left untreated 
(MED), treated with 40 ng/ml rhTFF2, pulsed with  
50 µg/ml OVA, or pretreated with rTFF2 and pulsed 
with 50 µg/ml OVA (TFF2 + OVA). Cells were analyzed 
at 96 h. Data show mean ± SE of triplicate wells.  
(C) BMDMs were transfected with siRNA specific for 
IL-33 (IL-33 siRNA) or scrambled control (control)  
48 h before the co-culture experiment described in B. 
IL-13 and IFN- protein levels were determined by 
ELISA, and mRNA levels of GATA3 and TBX21 were 
determined by quantitative RT-PCR. Mean ± SE of 
triplicate wells is shown. (D) BMDMs transfected with 
scrambled control or IL-33 siRNA were tested for  
IL-33 induction 96 h after treatment with OVA and  
40 ng/ml rTFF2. Mean ± SE of triplicate wells is 
shown. (E) GM-CSF differentiated BMDCs from naive 
WT C57BL/6 mice were stimulated as in B. Error bars 
indicate SE. (F) IL-33 protein levels in supernatants of 
WT versus MyD88/ BMDMs that were subjected to 
the co-culture conditions described in B. The experi-
ment was performed two times. Data show mean ± 
SE of triplicate wells. (G) Il33 mRNA expression and 
IL-33 protein levels from WT BMDMs that were ex-
posed to 1 µg/ml AMD3100 (CXCR4 antagonist) 24 h 
before exposure to stimulation with 40 ng/ml TFF2 or 
media for 48 h. Data show mean ± SE of triplicate 
wells. (H) GATA3 expression levels from co-cultures 
of WT naive CD4+ OTII cells and TI/ST2/ BMDMs 
that were treated with 40 ng/ml rTFF2 or left un-
treated before pulse with OVA (endotoxin <0.2 ng/ml 
free) and co-cultured with OTII cells for 96 h. Data 
show mean ± SE from triplicate wells. Data are repre-
sentative of two to four independent experiments  
(*, P < 0.05; **, P < 0.01; and ***, P < 0.001).
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tissue repair in several other systems (Farrell et al., 2002; 
Poulsen et al., 2005).
Although TFF2 may induce tissue repair directly, our data 
show that TFF2 was also a prerequisite for the initial produc-
tion of type 2 cytokines in the lung, as TFF2/ mice had 
impaired IL-4 and IL-13 responses at day 3 after inoculation 
compared with WT mice. This initial TH2 cell expansion at 
day 3 after infection was STAT-6 independent (unpublished 
data), as previously demonstrated by others (Jankovic et al., 
2000; van Panhuys et al., 2008). Although TFF2 played an 
essential role in the early phase of type 2 immunity against 
hookworms, during later stages of the response, the TFF2 
deficiency did not prevent the host from eventually produc-
ing sufficient levels of IL-4 to drive RELM-–dependent 
worm expulsion (Herbert et al., 2009). Furthermore, an early 
administration of rIL-4 to N. brasiliensis–infected TFF2/ 
mice rapidly increased RELM- levels and facilitated more 
rapid worm clearance. This demonstrated that TFF2/ mice 
had impaired immunity to N. brasiliensis infection because of 
an early defect in type 2 cytokines and that TFF2 functioned 
in a redundant manner with other TH2 effector molecules 
during the later stages of infection. This is not unexpected, as 
there are multiple redundant mechanisms that promote TH2 
responses (Neill et al., 2010; Paul and Zhu, 2010). Consistent 
with this hypothesis, repeated immunization of TFF2/ mice 
with chicken egg OVA over 3–4 wk resulted in only a mod-
erate reduction of eosinophilic inflammation (Nikolaidis et al., 
2006). Thus, TFF2 may primarily function to rapidly re-
spond to injurious agents and provide early instruction to-
ward TH2 development.
The epithelial-derived cytokines IL-25, IL-33, and TSLP 
are demonstrated regulators of type 2 immune responses 
(Fallon et al., 2006; Zaph et al., 2007; Humphreys et al., 2008). 
Thus, we postulated that TFF2 might induce type 2 immunity 
through inducing the production of one or more of these mol-
ecules. Surprisingly, TFF2 promoted IL-33 release from lung 
epithelia and alveolar macrophages within 24 h after infection. 
Even more striking was that TFF2 was required for IL-33 pro-
duction within inflammatory DCs recruited to the lung drain-
ing LNs by day 3 after infection. Given the recent demonstration 
that inflammatory DCs are central initiators of type 2 immu-
nity during allergic responses and worm infection (Hammad 
et al., 2010; Phythian-Adams et al., 2010), our data provide 
one potential mechanism underlying this capability. Our co-
culture experiments demonstrated that rTFF2 was sufficient to 
confer TH2-promoting abilities upon BMDMs and BMDCs. 
However, it remains possible that TFF2 might also induce TSLP 
and/or IL-25 under certain conditions, something which is 
supported by our demonstration that BMDMs produced IL-25 
when exposed to a combination of LPS and TFF2. Collec-
tively, our demonstration that TFF2 regulates IL-33 produc-
tion from both hematopoietic and nonhematopoietic cell 
lineages suggests that we have uncovered an important mecha-
nism of mucosal immunoregulation.
IL-33 is a well-established regulator of allergic lung inflam-
mation, anaphylactic shock, and colitis (Kurowska-Stolarska 
DISCUSSION
The molecular and cellular mechanisms that initiate type 2 
immunity remain topics of considerable debate and controversy. 
Although mechanistically unclear, most of the evidence sug-
gests that epithelial cells make important contributions to-
ward TH2 differentiation (Artis and Grencis, 2008; Paul and 
Zhu, 2010). Herein, we demonstrate that the epithelial- 
derived repair molecule TFF2 promotes the release of IL-33, 
an established regulator of type 2 inflammation. In mice, this 
mechanism is critical for allergic lung immunopathologies 
and the development of host immunity against hookworms. 
Moreover, we demonstrate that pediatric asthma is associated 
with an increase of mucosal TFF2 expression.
As type 2 cytokines have previously been shown to in-
duce TFF2 expression in the mouse lung (Nikolaidis et al., 
2003; Follettie et al., 2006), we investigated its functional 
role in both the HDM- and IL-13–induced models of allergic 
asthma. HDM-induced TH2 responses may result from the 
injurious effects of protease-containing allergens upon airway 
epithelia. Indeed, HDM antigens are a major cause of clinical 
asthma and TH2-driven allergic inflammation in humans 
(Karp, 2010). Similar to HDM antigens, rIL-13 administra-
tion in WT mice normally drives mucus hypersecretion, eosin-
ophil recruitment, and AHR (Wills-Karp et al., 1998). TFF2/ 
mice were significantly protected against most of the allergic 
features induced by either HDMs or IL-13. This suggests that 
TFF2 may function as an effector molecule of type 2 immu-
nity during murine asthma, which may partially explain how 
IL-13 causes airway epithelia to promote AHR, goblet cell 
activation, and mucus hypersecretion (Kuperman et al., 
2002). Consistent with this hypothesis, TFF2 is known to 
increase mucus viscosity, which is a contributing factor to 
airflow obstruction during asthma pathogenesis (Thim et al., 
2002; Agrawal et al., 2007). In addition, we show that chil-
dren experiencing acute asthma exacerbations expressed high 
levels of TFF2 mRNA in the nasal mucosa. Collectively, 
these results suggest that TFF2 release, perhaps in response to 
epithelial injury caused by allergens, serves an important role 
in the subsequent expression of type 2 cytokine–mediated 
immune responses in the allergic airway mucosa.
Given the central role of TFF family proteins in epithelial 
cell restitution after mucosal injury (Taupin and Podolsky, 2003), 
we examined the effects of TFF2 deficiency on hookworm-
induced lung pathology. Migration of N. brasiliensis L3 through 
lung tissue causes extensive hemorrhage during acute infec-
tion (Marsland et al., 2008). Pulmonary repair mechanisms 
subsequent to the exit of L3 from the lung result in pro-
gressive structural changes that resemble chronic obstructive 
pulmonary disorder and emphysema, in addition to the IL-13–
dependent processes that drive increased AHR (Marsland 
et al., 2008). Our study demonstrates that N. brasiliensis infec-
tion causes a rapid up-regulation of lung TFF2 expression 
(24 h), which functionally limits the extent of tissue injury 
caused by migratory L3, as TFF2/ mice show excessive hemo-
rrhage and accelerated development of emphysematous changes. 
This is consistent with TFF2’s known role in accelerating 
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development. IL-33 most likely works directly on the T cells and 
not through autocrine effects on BMDMs, as ST2/ macro-
phages also induced GATA3 expression after TFF2 treatment.
TFF2-mediated IL-33 production required the CXCR4 
receptor, which is a chemokine receptor used by T cell tropic 
strains of the human immunodeficiency virus (Grivel and 
Margolis, 1999). The natural ligand for CXCR4 is SDF-1 
(stromal cell–derived factor 1; Allen et al., 2004). Consistent 
with evidence that the TFF2 receptor is CXCR4, we dem-
onstrate that AMD3100 (a specific antagonist of CXCR4) 
blocks TFF2-induced IL-33 production. This is in concor-
dance with evidence that the CXCR4/SDF-1 axis is required 
for TH2-mediated allergic airway disease (Gonzalo et al., 2000) 
and that AMD3100 abolishes cockroach-induced murine 
asthma (Lukacs et al., 2002). Moreover, we have preliminary evi-
dence that AMD3100 treatment also exacerbates N. brasiliensis–
induced lung injury (unpublished data).
Our model predicts that TFF2 initiates a rapid, coordi-
nated type 2 immune response in the lung after allergen 
exposure or worm infection–induced mucosal injury. We 
propose the following: (a) within hours of insult, TFF2 secre-
tion drives epithelial cell restitution, which prevents exces-
sive hemorrhage and also starts the tissue remodeling process; 
(b) within 24 h, TFF2 promotes IL-33 release from lung epi-
thelia and alveolar macrophages, but although IL-33 produc-
tion in epithelia is rapidly lost, IL-33 production in myeloid 
cells is sustained for several days; (c) within 3 d, TFF2 pro-
motes IL-33 expression within ST2+ inflammatory DCs that 
migrate to draining LNs; (d) this results in the initial clonal 
burst of antigen-specific TH2 cells within the LN; and (e) 
once sufficient amounts of IL-4 and IL-13 are produced, 
these cytokines drive a myriad of effector functions within 
epithelia and macrophages (including TFF2 production) that 
promote worm expulsion and asthma pathogenesis (Kuperman 
et al., 2002; Herbert et al., 2009).
In the context of parasitic infections, the induction of type 
2 immunity and tissue remodeling protects the host against 
organ damage and pathogen persistence. However, in the 
context of asthma, excess production of type 2 cytokines and 
tissue repair molecules is pathogenic. It is possible that the 
TFF2/IL-33 axis may have evolved under selective pressure 
from parasitic helminths for the initiation of IL-4– and IL-13–
dependent host defense mechanisms, while simultaneously 
mediating the repair of damaged mucosa. This is consistent 
with the view that allergies and asthma represent maladaptive 
TH2 responses intended for worm parasites and suggests that 
TFF2 may be a possible target for therapeutic intervention in 
a broad array of allergic and parasitic human diseases.
MATERIALS AND METHODS
Mice, parasites, and asthma. All experiments used male WT C57BL/6 
or TFF2/ mice (C57BL/6 × 129) that have been backcrossed to the 
C57BL/6 background for more than six generations (Farrell et al., 2002). 
Although pure WT C57BL/6 B6 mice were used as controls throughout the 
paper, all infection data were additionally confirmed with +/+ and +/ 
littermate controls. 4Get mice on a BALB/c background have been described 
previously (Mohrs et al., 2001). Worm burdens were assessed by opening 
et al., 2008; Kearley et al., 2009; Pushparaj et al., 2009; Oboki 
et al., 2010; Rani et al., 2011). To date however, the biologi-
cally relevant signals for IL-33 release in the context of type 2 
pathologies have been unclear. Our study provides the follow-
ing insights: (a) TFF2 regulates IL-33 production, (b) hook-
worm infection results in IL-33 release into the lung tissue, and 
(c) pulmonary epithelia, alveolar macrophages, and inflamma-
tory DCs are important sources of IL-33. Chang et al. (2011) 
recently demonstrated that influenza-infected rodents have 
IL-33+ alveolar macrophages and develop IL-13–driven AHR. 
These data are remarkably consistent with the central conclu-
sions of our study, which are that infection-induced lung in-
jury causes TFF2 release that promotes IL-33 from innate 
sources for the rapid development of type 2 immunity.
IL-33 has been shown to regulate the immunobiology of 
DCs (Rank et al., 2009), basophils (Pecaric-Petkovic et al., 
2009), mast cells (Hsu et al., 2010), and T lymphocytes (Guo 
et al., 2009) and promote the development of alternatively acti-
vated macrophages (Kurowska-Stolarska et al., 2009; Zaiss et al., 
2011). We found that ST2 expression on macrophages was not 
essential in order for TFF2 to instruct these cells to drive antigen-
specific GATA3 expression within the CD4+ T cells, which 
implies that ST2 expression on T cells is sufficient for TH2 dif-
ferentiation. Indeed, ST2 was necessary for host protection 
against N. brasiliensis. This finding is consistent with evidence 
that mice deficient in IL-1RL11 (subunit of IL-33 receptor) 
show increased susceptibility to N. brasiliensis infection and that 
rIL-33 administration promotes the expulsion of the whip-
worm T. muris (Humphreys et al., 2008; Neill et al., 2010).
Although our data also support the notion that IL-33/
ST2 signaling promotes primary TH2 development (Townsend 
et al., 2000), there is controversy regarding whether ST2 sig-
naling promotes TH2 responses (Hoshino et al., 1999). Thus, 
we cannot rule out the possibility that IL-33 only functions 
to expand naive TH2 precursors (Guo et al., 2009). However, 
our data are consistent with reports that ST2 deletion or 
blockade impairs type 2 responses in vivo (Löhning et al., 1998; 
Coyle et al., 1999; Townsend et al., 2000). Thus, we propose 
that a TFF2/IL-33 axis exists, which serves an important 
function in the development of TH2 responses and host im-
munity against hookworm infection.
Several lines of evidence suggest that TFF2 preferentially 
drives type 2 inflammation and antigen-specific TH2 differen-
tiation through its ability to induce IL-33 production. First, 
rTFF2 could rapidly induce the selective recruitment of eo-
sinophils in 4Get mice through a mechanism that was blocked 
by inhibition of ST2, the critical subunit of the IL-33 recep-
tor. Second, TFF2 treatment of BMDMs or BMDCs co- 
cultured with OVA-specific CD4+ T cells (OTII) resulted in 
the specific induction of GATA-3, the TH2 lineage–specific 
transcription factor (Ouyang et al., 2000; Seki et al., 2004), as 
well as IL-13 production in culture supernatants. These cul-
tures also contained IL-5 but no IL-10, IFN-, or IL-17A 
(unpublished data). Lastly, IL-33 production from BMDMs 
was necessary to promote T cell differentiation toward a TH2 
phenotype and for the concomitant suppression of TH1 
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RPMI containing 0.5 mg/ml Liberase CI (Roche) and 0.5 mg/ml DNase I 
(Sigma-Aldrich) RPMI for 30 min at 37°C with shaking. Samples were fur-
ther disassociated by repeated passage through a 10-ml syringe fitted with an 
18-g needle and finally passed through a 70-µm cell strainer to obtain a single 
cell suspension. For cytokine measurements, BAL fluid was collected using es-
tablished protocols (Lewkowich et al., 2005) followed by concentration with 
Amicon Ultra centrifugal filter units with 3K cut-off (Millipore). Magnetic 
bead isolation of EpCAM- and CD11c-positive cells was performed according 
to the manufacturer’s protocol (Miltenyi Biotec)
Flow cytometric analyses. Single cell suspensions of lung or MLN tissue 
were stained with one or more of the following fluorescently labeled mAbs: 
ST2L/IL-1R4 (clone 245707) and anti–IL-33 (R&D Systems), CD11c 
(clone N418), CD11b (clone M1/70), anti-CD326/EpCAM (clone G8.8), 
I-Ab (clone AF6-120.1), Ly6G/C (clone RB6-8C5), FcRI (clone MAR-1), 
CD103 (clone 2E7), CD45 (clone 30-F11), CD317 (clone 120g8), and 
isotype control (MOPC-173; eBioscience). Before intracellular cytokine 
staining, cells were either stimulated with PMA/Ionomycin/Golgi-stop 
(BD) or 1 µg/ml anti-CD3/anti-CD28 mAb for 16 h, with Golgi-plug 
added the last 4 h before staining. Acquisition was performed with an LSRII 
flow cytometer (BD) or FACSCalibur (BD), and data were analyzed with 
FlowJo software (version 8.8; Tree Star). Rat anti–mouse ST2 (clone M955) 
and control IgG antibodies were provided by Amgen.
Generation of macrophages, DCs, and basophils. BMDMs were 
grown in CMG media from an M-CSF transfected cell line, as described 
previously (Herbert et al., 2010). BMDCs were grown in media containing 
20 ng/ml GM-CSF for 9 d. BM-derived basophils were generated from total 
BM cultured with 10 ng/ml IL-3 for 6 d.
OTII differentiation assay. CD4+ cells were isolated from naive OVA-
specific TCR transgenic mice (OTII) as previously described (Herbert et al., 
2010). BMDMs were either left untreated or exposed to recombinant 
human TFF2 (endotoxin values <0.1 ng/ml [PeproTech]) for 16 h and then 
pulsed with 50 µg/well endotoxin-free chicken egg OVA for 8 h, washed 
several times, and co-cultured with purified naive OTII CD4+ cells at a ratio 
of 10:1 (CD4+/M) for 72–96 h. IL-33 and scrambled control small inter-
fering RNA (siRNA) BMDMs were electroporated with scrambled control 
or IL-33 siRNA (Thermo Fisher Scientific) using the Amaxa mouse macro-
phage Nucleofector kit according to manufacturer’s instruction (Lonza).
In vivo cytokine capture assays. Relative amounts of in vivo IL-4 secre-
tion were determined by the in vivo cytokine capture assay (Finkelman and 
Morris, 1999). Injected biotin-labeled anticytokine mAbs in this assay form 
complexes with the secreted cytokines they specifically bind that have a 
much longer in vivo half-life than free cytokines. Consequently, the com-
plexes accumulate in vivo and can be measured by ELISA, using wells coated 
with mAbs that bind to an epitope on the cytokine that is not blocked by the 
injected mAb. Bound biotin-mAb/cytokine complexes are detected with 
horseradish peroxidase–streptavidin, followed by a luminogenic substrate. 
To measure IL-4 and IFN- secretion, mice were injected i.v. with 10 µg 
biotin-BVD4-1D11 (anti–IL-4 mAb), and serum was collected 6 h later and 
analyzed with microtiter plate wells coated with BVD6-24G2.3 (anti–IL-4). 
These antibodies were purified from ascites by ion-exchange chromatogra-
phy as previously described (Herbert et al., 2008).
Long-acting IL-4 (IL-4C). IL-4/anti–IL-4 mAb complexes (IL-4C) were 
prepared by mixing rmIL-4 with the rat IgG1 anti–IL-4 mAb, 11B11, at a 2:1 
molar (1:5 weight) ratio. Mice were injected i.p. with IL-4C containing 5 µg IL-4 
and 25 µg anti–mouse IL-4 (11B11). IL-4C slowly dissociated, releasing biologi-
cally active IL-4 for 3–5 d. Because IL-4C contain only one molecule of IgG 
mAb and 11B11 blocks IL-4R binding of IL-4, IL-4C do not activate comple-
ment, interact more strongly with Fc receptors than monomeric IgG of the 
same rat IgG2b isotype, or bind to IL-4R. IL-4C do not promote worm expul-
sion or cell differentiation in IL-4R–deficient mice (Herbert et al., 2009)
mouse intestines longitudinally and incubating them in PBS at 37°C for 3 h 
in a modified Baermann apparatus in which tissues were placed in a sieve 
atop a 250-ml beaker. Parasites that collected at the bottom were counted. 
For fecal egg counts, feces were collected, weighed, and incubated in satu-
rated NaCl solution, and eggs were counted using McMaster slides (Herbert 
et al., 2009). Allergic airway responses induced by HDMs or 5 µg rmIL-13 
have been described previously (Wills-Karp et al., 1998) The Institutional 
Animal Care and Use Committee at the Cincinnati Children’s Hospital 
Medical Center (CCHMC) approved all protocols and procedures.
Subjects. Nasal epithelial samples were obtained from healthy and asth-
matic children at CCMHC and processed for RNA extraction and cDNA 
synthesis as previously described (Guajardo et al., 2005). Asthmatic chil-
dren and their parents attending the hospital clinics and emergency depart-
ment in the CCHMC were invited to participate in the study. Participants 
were included in exacerbation of asthma (asthma-E group, n = 23) or 
healthy nonatopic children (control group, n = 9), as previously described 
(Guajardo et al., 2005).
Assessment of airway responsiveness and BAL cellularity. To eval-
uate airway responses, mice were anaesthetized, intubated, and respirated 
at a rate of 120 breaths per minute with a constant tidal volume (0.2 ml) 
and paralyzed with 25 mg/kg decamethonium bromide 24 h after the final 
HDM or IL-13 challenge. 50 µg/kg acetylcholine was injected into the in-
ferior vena cava, and dynamic airway pressure (cm H2O × sec) was fol-
lowed for 5 min. To collect BAL fluid, lungs were lavaged three times 
with a 1.0-ml aliquot of cold Hanks’ balanced salt solution (Invitrogen). 
Recovered lavage fluid (70–80%) was centrifuged (300 g for 10 min), and 
the cell pellet was resuspended in 1.0 ml of 10% FBS in PBS. Total cells 
were counted with a hemocytometer. Slides were prepared by cytocen-
trifugation (Cytospin 3; Shandon Instruments) and stained with Diff-Quik 
(Dade Behring). BAL cell differential counts were determined using mor-
phological criteria under a light microscope (BX40; Olympus) with evalu-
ation of ≥500 cells/slide.
Lung histopathology. To assess airway inflammation and mucus cell con-
tent in the airway wall, lungs were excised and fixed in 10% formalin, 
washed in methanol, dehydrated and embedded in paraffin, and cut into 
5-µm sections. Sections were mounted on slides and stained with hematoxylin 
and eosin and periodic acid Schiff (PAS). The left lung was removed and 
fixed in 10% neutral buffered formalin. Lungs were bisected and oriented cut 
side down in a paraffin block such that sections would reveal cross sections 
of consistent airways for comparison. Two, 5-µm sections, 30 µm apart, 
were PAS stained and examined for mucin production. Examination in-
cluded assessment of the percentage of airways with PAS-positive cells 
(number of airways containing any PAS cells/number of total airways) as 
well as total number of goblet cells per section.
Microscopy/histology. 5-mm formalin-fixed, paraffin-embedded sections 
of lung or jejunum were prepared by the CCHMC Morphology core. A mi-
croscope (Eclipse E600; Nikon) fitted with a 40× objective oil-immersion 
lens (Plan Apochromat; Nikon) was used for image acquisition, and photos 
were captured with a SPOT Diagnostics RT slider digital color camera using 
a SPOT Diagnostics imaging system.
ELISA and real-time PCR. RNA was DNase I treated and cDNA pre-
pared using SuperScript II reverse transcription (Invitrogen). Real-time PCR 
was performed on a Gene Amp 7500 instrument (PE Biosystems) with the 
Syber Green detection reagent. Cycle threshold (CT) values for genes evalu-
ated were determined and expressed using the 1/ct method (Table S1), as 
described previously (Herbert et al., 2010). Mouse cytokine ELISA kits spe-
cific for IL-13, IFN-, and IL-33 were obtained from eBioscience.
Isolation of lung tissue cells and BAL collection. Lungs were perfused 
with 1× PBS and minced with scissors followed by digestion in serum-free 
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